Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 13/20 | 0.49 |
| ▸ | NMBR | P28336 | 1/20 | 0.43 |
| ▸ | HRAS | P01112 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CTSL | P07711 | 1/20 | 0.37 |
| ▸ | CTSB | P07858 | 1/20 | 0.37 |
| ▸ | CTSS | P25774 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6813616 | 1.00 | SIRT2 (0.49) | SIRT2NMBRHRASMEN1KMT2A | |
| SCHEMBL6810651 | 0.90 | SIRT2 (0.48) | SIRT2NMBRHRAS | |
| SCHEMBL7712921 | 0.90 | SIRT2 (0.48) | SIRT2NMBRHRAS | |
| SCHEMBL6809094 | 0.88 | SIRT2 (0.49) | SIRT2HRAS | |
| SCHEMBL6809102 | 0.88 | SIRT2 (0.49) | SIRT2HRAS | |
| SCHEMBL6813733 | 0.85 | SIRT2 (0.47) | SIRT2NMBRHRAS | |
| SCHEMBL6813730 | 0.85 | SIRT2 (0.47) | SIRT2NMBRHRAS | |
| SCHEMBL6813557 | 0.84 | SIRT2 (0.52) | SIRT2NMBRHRAS | |
| SCHEMBL6809104 | 0.83 | HRAS (0.53) | SIRT2HRAS | |
| SCHEMBL6809101 | 0.83 | HRAS (0.53) | SIRT2HRAS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1076663-B1 | FUNCTIONALIZED ALKYL AND ALKENYL SIDE CHAIN DERIVATIVES OF GLYCINAMIDES AS FARNESYL TRANSFERASE INHIBITORS | WARNER LAMBERT CO (US) | 2004-02-18 | — | — | EP | disclosed |
| US-6369034-B1 | FOR THERAPY OF CANCER, RESTENOSIS, AND ATHEROSCLEROSIS | WARNER-LAMBERT COMPANY | 2002-04-09 | — | — | US | disclosed |